Daniel F Connor
Overview
Explore the profile of Daniel F Connor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
1484
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Connor D, Ford J, Pearson G, Scranton V, Dusad A
J Child Adolesc Psychopharmacol
. 2017 Aug;
27(10):875-883.
PMID: 28829159
Objective: To assess patient characteristics and clinician-rated outcomes for children diagnosed with early-onset bipolar disorder in comparison to a depressive disorders cohort from a single clinic site. To assess predictors...
12.
Mehdi A, Schweinsburg B, Zehgeer A, Connor D, Luber M, Coffey B
J Child Adolesc Psychopharmacol
. 2016 Dec;
26(10):944-947.
PMID: 27992258
No abstract available.
13.
Connor D, Pearson G
Acad Psychiatry
. 2016 Nov;
41(2):299-300.
PMID: 27837453
No abstract available.
14.
Connor D
J Child Adolesc Psychopharmacol
. 2016 Feb;
26(1):2-3.
PMID: 26835875
No abstract available.
15.
Connor D
Paediatr Drugs
. 2015 Aug;
17(5):361-71.
PMID: 26233632
Attention-deficit hyperactivity disorder (ADHD) is a common developmental neurobiological condition of childhood characterized by age-inappropriate degrees of hyperactivity/impulsivity and inattention to tasks requiring sustained vigilance. Oppositional defiant disorder (ODD) is...
16.
Adjei A, Teuscher N, Kupper R, Chang W, Greenhill L, Newcorn J, et al.
J Child Adolesc Psychopharmacol
. 2014 Dec;
24(10):570-8.
PMID: 25514542
Objectives: The purpose of this study was to evaluate the relative bioavailability and safety of a multilayer extended-release bead methylphenidate (MPH) hydrochloride 80 mg (MPH-MLR) capsule or sprinkles (37% immediate-release...
17.
Wigal S, Greenhill L, Nordbrock E, Connor D, Kollins S, Adjei A, et al.
J Child Adolesc Psychopharmacol
. 2014 Dec;
24(10):562-9.
PMID: 25470572
Objective: The purpose of this study was to assess the time of onset and time course of efficacy over 12.0 hours of extended-release multilayer bead formulation of methylphenidate (MPH-MLR) compared...
18.
Arnsten A, Raskind M, Taylor F, Connor D
Neurobiol Stress
. 2014 Dec;
1:89-99.
PMID: 25436222
Research on the neurobiology of the stress response in animals has led to successful new treatments for Post-Traumatic Stress Disorder (PTSD) in humans. Basic research has found that high levels...
19.
Grasso D, Connor D, Scranton V, Macary S, Honigfeld L
Clin Pediatr (Phila)
. 2014 Aug;
54(8):796-9.
PMID: 25106946
No abstract available.
20.
Connor D, Arnsten A, Pearson G, Greco G
Expert Opin Pharmacother
. 2014 Jul;
15(11):1601-10.
PMID: 24992513
Introduction: Guanfacine extended release (GXR) is a selective α(2A)-adrenoreceptor agonist originally developed as an antihypertensive agent and now FDA approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) as monotherapy and...